1239 related articles for article (PubMed ID: 10482933)
1. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
2. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
3. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
4. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
5. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
[TBL] [Abstract][Full Text] [Related]
6. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
7. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
[TBL] [Abstract][Full Text] [Related]
9. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
10. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
[TBL] [Abstract][Full Text] [Related]
11. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
13. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
15. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
16. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A
Haematologica; 1999 Oct; 84(10):905-10. PubMed ID: 10509038
[TBL] [Abstract][Full Text] [Related]
17. [Intensive treatment of multiple myeloma].
Harousseau JL
Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
[TBL] [Abstract][Full Text] [Related]
18. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
19. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
